Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability.

Our pipeline covers cardiovascular, metabolic, and rare genetic diseases, with multiple programs already in the clinic:
YOLT-201 (ATTR): advancing towards Phase III clinical trial.
YOLT-101 (HeFH): received dual regulatory clearances in China and the U.S.
YOLT-204 (TDT/SCD): ongoing in IIT clinical trials.
YOLT-203 (PH1): global phase II clinical trial of YOLT-203-PH1 is conducting.

YolTech Therapeutics

Yuxuan Wu

This department oversees the strategic direction and overall management of the organization.

YolTech Therapeutics

Org chart

Teams

Executive Leadership

Offices

YolTech Therapeutics

Org chart

Teams

Executive Leadership

Offices

Related companies